INSM
Insmed
Pharmaceutical Preparations · Health Care
$104.44-4.46%
Quote via Yahoo Finance, may be delayed · 2026-11-03 · 4:00 PM ET
Daily prices: Yahoo Finance, split-adjusted. As of 2026-11-03.
Drag across the line to read a price. Dots mark earnings, filings and dividends.
Very weak profile
Revenue CAGR, 3Y lifts this profile the most.
As of 2025-12-31. Latest quarter ended 2026-09-30. v1 methodology, subject to change.
The profile score is 4 points lower since last quarter. Momentum is 21 points lower. Debt and safety is 1 point lower.
Sector rank 46 of 46
In plain English
- Insmed operates in Pharmaceutical Preparations.
- Latest-year revenue was 0.6 billion.
- The profile score is 23, a Very weak profile. Growth is the strongest listed input.
Written from the figures on this page. No language model was called. It may still be wrong. Not advice.
As of 2025-12-31. Latest quarter ended 2026-09-30. SEC EDGAR companyfacts, fetched 2026-11-01. SEC filing
Financials
Tap a column to read the value.
P/E vs own history
Not shown while earnings are negative.
Earnings
Actual earnings per share from EDGAR filings. Historical estimates are not used.
Actual from EDGAR
Data confidence
The Company Score summarises financial characteristics relative to similar companies using a published formula. It does not predict future returns.
SEC EDGAR companyfacts, fetched 2026-11-01.